News

Gadget Review on MSN4dOpinion
Regeneron Just Bought Your DNA From 23andMe for $2.56
Regeneron acquires bankrupt 23andMe for $256M. What this DNA data sale means for privacy, pharma, and your genetic ...
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
The Hudson Independent2d
Regeneron Enters into Agreement to Acquire Consumer Genetics Business
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...
23andMe sold to biotech company Regeneron for $256 million
Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...
Daily Voice on MSN4d
Westchester-Based Regeneron Buying Bankrupt 23andMe For $256M, Pledges To Protect DNA Data
Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...
Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...
Stocktwits on MSN5d
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts
Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology ...